Cite
HARVARD Citation
Pilling, A. et al. (2019). Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration‐resistant prostate cancer cells to enzalutamide. Prostate. 79 (11), pp. 1347-1359. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Pilling, A. et al. (2019). Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration‐resistant prostate cancer cells to enzalutamide. Prostate. 79 (11), pp. 1347-1359. [Online].